

10/669,905

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:32:54 ON 13 DEC 2004

=> file biosis medline caplus wpids uspatfull
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 09:33:43 ON 13 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'MEDLINE' ENTERED AT 09:33:43 ON 13 DEC 2004

FILE 'CAPLUS' ENTERED AT 09:33:43 ON 13 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 09:33:43 ON 13 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 09:33:43 ON 13 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

=> s (zinc or zn) and aspartic and fructose
L1 1803 (ZINC OR ZN) AND ASPARTIC AND FRUCTOSE

=> s l1 and antiviral
L2 338 L1 AND ANTIVIRAL

=> s l2 and zinc oxide
L3 55 L2 AND ZINC OXIDE

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 54 DUP REM L3 (1 DUPLICATE REMOVED)

=> s l4 and aspartic acid
L5 45 L4 AND ASPARTIC ACID

=> d l5 bib abs

L5 ANSWER 1 OF 45 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:559505 BIOSIS
DN PREV200300562337
TI Anti-viral composition.
AU Killam, Harold [Inventor, Reprint Author]
CS 6 Howard St., Melrose, MA, 02176, USA
PI US 6638915 October 28, 2003
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Oct 28 2003) Vol. 1275, No. 4. <http://www.uspto.gov/web/menu/patdata.html>
. e-file.
ISSN: 0098-1133 (ISSN print)..
DT Patent
LA English
ED Entered STN: 26 Nov 2003
Last Updated on STN: 26 Nov 2003
AB The invention relates to **antiviral** compositions comprising a

mixture comprising **zinc oxide, aspartic acid**, and high **fructose** corn syrup, and to methods of making and using such compositions.

=>.d 15 bib abs 2-45

L5 ANSWER 2 OF 45 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:31269 CAPLUS
DN 136:90977
TI **Antiviral** composition containing **zinc oxide**
IN Killam, Harold
PA Alpha Solar Corporation, USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002002130	A1	20020110	WO 2001-US20579	20010628
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6638915	B1	20031028	US 2000-608029	20000630
	CA 2412676	AA	20020110	CA 2001-2412676	20010628
	US 2002099022	A1	20020725	US 2001-39968	20011019
	US 6500808	B2	20021231		
	US 2004072733	A1	20040415	US 2003-669905	20030924
PRAI	US 2000-608029	A	20000630		
	WO 2001-US20579	W	20010628		

AB The invention relates to **zinc**-containing **antiviral** compns. and methods of treating viral infections. More specifically, the invention provides compns. and methods useful for ameliorating the symptoms of individuals suffering from infection with a broad range of viruses. Examples of viruses against which the compds. of the invention are active include rhinoviruses, varicella zoster, immunodeficiency viruses, including HIV. A composition containing D- and L-**aspartic acid**, ZnO, and high **fructose** corn syrup was effective in ameliorating the symptoms of the common cold in humans.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 45 USPATFULL on STN
AN 2004:308094 USPATFULL
TI Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
IN Feldstein, Mikhail M., Moscow, RUSSIAN FEDERATION
Bairamov, Danir F., Moscow, RUSSIAN FEDERATION
Plate, Nicolai A., Moscow, RUSSIAN FEDERATION
Kulchikhin, Valery G., Moscow, RUSSIAN FEDERATION
Singh, Parminder, San Francisco, CA, UNITED STATES
Cleary, Gary W., Los Altos Hills, CA, UNITED STATES
PI US 2004242770 A1 20041202
AI US 2004-825083 A1 20040414 (10)
PRAI US 2003-463627P 20030416 (60)

DT Utility
FS APPLICATION
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 3505
AB A water-insoluble, hydrophilic adhesive polymer is provided, wherein the polymer is prepared by polymerization of a composition consisting of a hydrophilic monomer and a dual-function monomer that both (a) undergoes polymerization with the hydrophilic monomer and (b) provides crosslinks in the polymer product. Water-insoluble, hydrophilic adhesive polymer blends are also provided, which are free of covalent crosslinks. The polymers are useful in hydrogel and bioadhesive compositions, which find utility as drug delivery systems (e.g., topical, transdermal, transmucosal, iontophoretic), medical skin coverings, wound dressings and wound healing products, biomedical electrodes, and tooth whitening stripes.

L5 ANSWER 4 OF 45 USPATFULL on STN
AN 2004:258641 USPATFULL
TI COATED PARTICLES, METHODS OF MAKING AND USING
IN Anderson, David, Colonial Heights, VA, UNITED STATES
PI US 2004201117 A1 20041014
AI US 2003-624498 A1 20030723 (10)
RLI Continuation of Ser. No. US 2002-170237, filed on 13 Jun 2002, GRANTED, Pat. No. US 6638621 Continuation-in-part of Ser. No. US 2000-297997, filed on 16 Aug 2000, GRANTED, Pat. No. US 6482517 Continuation-in-part of Ser. No. WO 1998-US18639, filed on 8 Sep 1998, PENDING
PRAI WO 1998-US18639 19980908
US 1997-58309P 19970909 (60)

DT Utility
FS APPLICATION
LREP WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190
CLMN Number of Claims: 67
ECL Exemplary Claim: CLM-1-107
DRWN 11 Drawing Page(s)
LN.CNT 5395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least on nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 45 USPATFULL on STN
AN 2004:132941 USPATFULL
TI Individualization of therapy with anesthetics
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA Xanthus Life Sciences, Inc., Cambridge, MA (U.S. corporation)
PI US 2004101477 A1 20040527
AI US 2002-307210 A1 20021127 (10)
DT Utility

FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 5230

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with anesthetics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 45 USPATFULL on STN
AN 2004:112038 USPATFULL
TI Individualization of therapy with anticoagulants
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA Xanthus Life Sciences, Inc., Cambridge, MA (U.S. corporation)
PI US 2004084867 A1 20040506
AI US 2003-607848 A1 20030627 (10)
PRAI US 2002-391976P 20020628 (60)

DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 123
ECL Exemplary Claim: 1
DRWN 26 Drawing Page(s)
LN.CNT 7621

AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with anticoagulants.

L5 ANSWER 7 OF 45 USPATFULL on STN
AN 2004:95279 USPATFULL
TI Anti-viral composition
IN Killam, Harold, Melrose, MA, UNITED STATES
PI US 2004072733 A1 20040415
AI US 2003-669905 A1 20030924 (10)
RLI Continuation of Ser. No. US 2000-608029, filed on 30 Jun 2000, GRANTED,
Pat. No. US 6638915

DT Utility
FS APPLICATION
LREP Harold Killam, Alpha Solar Corporation, 6 Howard Street, Melrose, MA,
02176
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1060

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to **zinc**-containing **antiviral**
compositions and methods of treating viral infections. More
specifically, the invention provides compositions and methods useful for
ameliorating the symptoms of individuals suffering from infection with a
broad range of viruses. Examples of viruses against which the compounds
of the invention are active include rhinoviruses, varicella zoster,
immunodeficiency viruses, including HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 45 USPATFULL on STN
AN 2004:82367 USPATFULL
TI Wound healing compound
IN Peshoff, Mickey L., Sulphur, LA, UNITED STATES
PI US 2004062817 A1 20040401
AI US 2003-675339 A1 20030930 (10)
RLI Division of Ser. No. US 2002-125165, filed on 18 Apr 2002, GRANTED, Pat.
No. US 6660306 Continuation-in-part of Ser. No. US 2000-689087, filed on
12 Oct 2000, ABANDONED
DT Utility
FS APPLICATION
LREP THOMAS S. KEATY, KEATY PROFESSIONAL LAW CORP., 2140 WORLD TRADE CENTER,
NO. 2 CANAL STREET, NEW ORLEANS, LA, 70130
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2188

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic antibacterial/antifungal-wound
healing compositions comprise a therapeutically effective amount of
antibacterial agents and/or antifungal agents and/or wound healing
composition alone. In one embodiment, the wound healing composition
comprises (a) **zinc oxide** and (b) fat-soluble
vitamins. The therapeutic antibacterial/antifungal-wound healing
compositions may be utilized in a wide variety of pharmaceutical
products. This invention also relates to methods for preparing and using
the antibacterial/antifungal-wound healing compositions and the
pharmaceutical products in which the therapeutic compositions may be
used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 45 USPATFULL on STN
AN 2003:277323 USPATFULL
TI Individualization of therapy with **antiviral** agents
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA Xanthus Life Sciences, Inc, Cambridge, MA (U.S. corporation)
PI US 2003195350 A1 20031016
AI US 2002-307204 A1 20021127 (10)
PRAI US 2001-333500P 20011128 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with **antiviral** agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 45 USPATFULL on STN
AN 2003:276420 USPATFULL
TI Compositions and methods of use of peptides in combination with biocides
and/or germicides

IN Kuhner, Carla H., Avondale, PA, UNITED STATES
Romesser, James A., Kennett Square, PA, UNITED STATES
PI US 2003194445 A1 20031016
AI US 2001-5931 A1 20011112 (10)
DT Utility
FS APPLICATION
LREP Patrick J. Farley, Ph.D., Woodcock Washburn LLP, One Liberty Place -
46th Floor, Philadelphia, PA, 19103
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptide compositions and methods for inhibiting and controlling the growth of microbes using peptides possessing antimicrobial activity are described. The composition comprises at least one antimicrobial peptide in combination with at least one biocide, germicide, preservative or antibiotic. The method comprises administering an amount of the peptide composition effective for the prevention, inhibition or termination of microbes in industrial and clinical settings.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 45 USPATFULL on STN
AN 2003:271068 USPATFULL
TI Use of metabolic phenotyping in individualized treatment with amonafide
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003190671 A1 20031009
AI US 2002-124747 A1 20020416 (10)
RLI Continuation-in-part of Ser. No. US 2002-87996, filed on 28 Feb 2002,
PENDING
PRAI US 2001-271714P 20010228 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN 31 Drawing Page(s)
LN.CNT 8446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 45 USPATFULL on STN
AN 2003:265324 USPATFULL
TI Individualization of therapy with antibiotic agents
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CA (U.S. corporation)
PI US 2003186339 A1 20031002
AI US 2002-151467 A1 20020517 (10)
PRAI US 2001-291336P 20010517 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 83

ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5674

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antibiotic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 45 USPATFULL on STN

AN 2003:257772 USPATFULL

TI Individualization of therapy with antihistamines

IN Leyland-Jones, Brian, Miami, FL, UNITED STATES

PA Xanthus Life Sciences, Inc., Cambridge, MA (U.S. corporation)

PI US 2003180823 A1 20030925

AI US 2002-325466 A1 20021219 (10)

PRAI US 2001-340827P 20011219 (60)

DT Utility

FS APPLICATION

LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

CLMN Number of Claims: 93

ECL Exemplary Claim: 1

DRWN 23 Drawing Page(s)

LN.CNT 5019

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antihistamines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 45 USPATFULL on STN

AN 2003:250547 USPATFULL

TI Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin

IN Shefer, Adi, East Brunswick, NJ, UNITED STATES

Shefer, Samuel, East Brunswick, NJ, UNITED STATES

PI US 2003175333 A1 20030918

AI US 2003-376736 A1 20030228 (10)

RLI Continuation-in-part of Ser. No. US 2002-91935, filed on 6 Mar 2002, PENDING

DT Utility

FS APPLICATION

LREP Diane Dunn McKay, Mathews, Collins, Shepherd & McKay, P.A., Suite 306, 100 Thanet Circle, Princeton, NJ, 08540

CLMN Number of Claims: 50

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1615

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling matrix layer. The matrix layer comprises water-sensitive, bioadhesive, film forming polymers, a water soluble oligomer, and a surfactant. The cosmetic, dermatological, and pharmaceutical active ingredients are soluble or

dispersed in the matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily removed without causing skin irritation or leaving adhesive residue on the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 45 USPATFULL on STN
AN 2003:250542 USPATFULL
TI Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
IN Shefer, Adi, East Brunswick, NJ, UNITED STATES
Shefer, Shmuel David, East Brunswick, NJ, UNITED STATES
PI US 2003175328 A1 20030918
AI US 2002-91935 A1 20020306 (10)
DT Utility
FS APPLICATION
LREP Mathews, Collins, Shepherd & McKay, P.A., Suite 360, 100 Thanet Circle, Princeton, NJ, 08540
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a patch for controlled topical or transdermal delivery of effective levels of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin, hair follicles, and sebaceous glands, with minimal discomfort and ease of use. The patch can be transparent or clear and comprises a rate-controlling polymeric matrix layer. The polymeric matrix layer comprises water-soluble, bioadhesive, film forming polymers. The cosmetic, dermatological, and pharmaceutical active ingredients are soluble or dispersed in the polymeric matrix. The patch becomes tacky when wetted and adheres onto the skin. The adhesive properties of the patch are sufficient to maintain the patch in place on the skin for the recommended treatment period while allowing the patch to be readily removed without causing skin irritation or leaving adhesive residue on the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 45 USPATFULL on STN
AN 2003:250425 USPATFULL
TI Individualization of therapy with anxiolitics
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003175210 A1 20030918
AI US 2002-100272 A1 20020314 (10)
PRAI US 2001-275493P 20010314 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 4933

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anxiolytic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 45 USPATFULL on STN
AN 2003:243899 USPATFULL
TI Hydrogel compositions
IN Cleary, Gary W., Los Altos Hills, CA, UNITED STATES
Parandoosh, Shoreh, Menlo Park, CA, UNITED STATES
Feldstein, Mikhail M., Moscow, RUSSIAN FEDERATION
Chalykh, Anatoly E., Moscow, RUSSIAN FEDERATION
PI US 2003170308 A1 20030911
AI US 2002-137664 A1 20020501 (10)
PRAI US 2001-288008P 20010501 (60)
DT Utility
FS APPLICATION
LREP David E. Newhouse, Esq., Newhouse & Associates, 477 Ninth Avenue 112,
San Mateo, CA, 94402-1858
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2528

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hydrogel compositions are provided (a) that have a continuous hydrophobic phase and a discontinuous hydrophilic phase, (b) that have a discontinuous hydrophilic phase and a continuous hydrophilic phase, or (c) that are entirely composed of a continuous hydrophilic phase. The hydrophobic phase, if present, is composed of a hydrophobic polymer, particularly a hydrophobic pressure-sensitive adhesive (PSA), a plasticizing elastomer, a tackifying resin, and an optional antioxidant. The discontinuous hydrophilic phase, if present, is composed of a crosslinked hydrophilic polymer, particularly a crosslinked cellulosic polymer such as crosslinked sodium carboxymethylcellulose. For those hydrogel compositions containing a continuous hydrophilic phase, the components of the phase include a cellulose ester composition or an acrylate polymer or copolymer, and a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding thereto. Films prepared from hydrogel compositions containing or entirely composed of the aforementioned continuous hydrophilic phase can be made translucent, and may be prepared using either melt extrusion or solution casting. A preferred use of the hydrogel compositions is in wound dressings, although numerous other uses are possible as well.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 45 USPATFULL on STN
AN 2003:243767 USPATFULL
TI Individualization of therapy with antipsychotics
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003170176 A1 20030911
AI US 2002-100230 A1 20020314 (10)
PRAI US 2001-275462P 20010314 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 5181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis

of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antipsychotic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 45 USPATFULL on STN
AN 2003:200394 USPATFULL
TI Use of metabolic phenotyping in individualized treatment with amonafide
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PI US 2003138377 A1 20030724
AI US 2002-87996 A1 20020228 (10)
PRAI US 2001-271714P 20010228 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 88
ECL Exemplary Claim: 1
DRWN 29 Drawing Page(s)
LN.CNT 8181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 45 USPATFULL on STN
AN 2003:200392 USPATFULL
TI Individualization of therapy with Alzheimer's disease agents
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003138375 A1 20030724
AI US 2002-164854 A1 20020606 (10)
PRAI US 2001-295860P 20010606 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 5332

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with Alzheimer's disease agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 45 USPATFULL on STN
AN 2003:188634 USPATFULL
TI Two-phase, water-absorbent bioadhesive composition
IN Cleary, Gary W., Los Altos Hills, CA, UNITED STATES
Feldstein, Mikhail M., Moscow, RUSSIAN FEDERATION
Kulichikhin, Valery G., Moscow, RUSSIAN FEDERATION
Bairamov, Danir F., Moscow, RUSSIAN FEDERATION
PI US 2003130427 A1 20030710
US 6803420 B2 20041012

AI US 2002-137196 A1 20020501 (10)
PRAI US 2001-288024P 20010501 (60)
DT Utility
FS APPLICATION
LREP REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1751

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An adhesive composition is provided that contains both a hydrophobic phase and a hydrophilic phase, wherein the hydrophobic phase is composed of a crosslinked hydrophobic polymer composition and the hydrophilic phase is a water-absorbent blend of a hydrophilic polymer and a complementary oligomer capable of crosslinking the hydrophilic polymer through hydrogen bonding, ionic bonding, and/or covalent bonding. The composition is useful as a bioadhesive, for affixing drug delivery systems, wound dressings, bandages, cushions, or the like to a body surface such as skin or mucosal tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 45 USPATFULL on STN
AN 2003:180806 USPATFULL
TI Individualization of therapy with antiarrhythmics
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003124636 A1 20030703
AI US 2002-125693 A1 20020417 (10)
PRAI US 2001-284191P 20010418 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 4925

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antiarrhythmics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 45 USPATFULL on STN
AN 2003:159130 USPATFULL
TI Coated particles, methods of making and using
IN Anderson, David M., Colonial Heights, VA, UNITED STATES
PI US 2003108743 A1 20030612
US 6638621 B2 20031028
AI US 2002-170237 A1 20020613 (10)
RLI Continuation-in-part of Ser. No. US 2000-297997, filed on 16 Aug 2000, GRANTED, Pat. No. US 6482517
DT Utility
FS APPLICATION
LREP WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190
CLMN Number of Claims: 107
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)

LN.CNT 5538

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least one nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 45 USPATFULL on STN

AN 2003:158871 USPATFULL

TI Individualization of therapy with antineoplastic agents

IN Leyland-Jones, Brian, Miami, FL, UNITED STATES

PA McGill University (U.S. corporation)

PI US 2003108484 A1 20030612

AI US 2002-135185 A1 20020429 (10)

PRAI US 2001-287014P 20010430 (60)

DT Utility

FS APPLICATION

LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

CLMN Number of Claims: 83

ECL Exemplary Claim: 1

DRWN 24 Drawing Page(s)

LN.CNT 5265

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antineoplastic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 45 USPATFULL on STN

AN 2003:133890 USPATFULL

TI Multiple determinants for metabolic phenotypes

IN Leyland-Jones, Brian, Miami, FL, UNITED STATES

PI US 2003091975 A1 20030515

AI US 2002-72611 A1 20020208 (10)

PRAI US 2001-267472P 20010209 (60)

DT Utility

FS APPLICATION

LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

CLMN Number of Claims: 56

ECL Exemplary Claim: 1

DRWN 29 Drawing Page(s)

LN.CNT 5948

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the determination of multiple phenotypic determinants for human drug metabolizing enzymes. More specifically, the present invention relates to the characterization of metabolic phenotypes based on phenotypic determinants and applications and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 45 USPATFULL on STN
AN 2003:112492 USPATFULL
TI Individualization of therapy with analgesics
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003077222 A1 20030424
AI US 2002-141533 A1 20020507 (10)
PRAI US 2001-288786P 20010507 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 99
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5316
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with analgesics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 45 USPATFULL on STN
AN 2003:106222 USPATFULL
TI Individualization of therapy with erectile dysfunction agents
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003073133 A1 20030417
AI US 2002-134296 A1 20020426 (10)
PRAI US 2001-286336P 20010426 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 93
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with ED agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 45 USPATFULL on STN
AN 2003:105800 USPATFULL
TI Individualization of therapy with antidepressants
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003072710 A1 20030417
AI US 2002-100218 A1 20020314 (10)
PRAI US 2001-275490P 20010314 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 83

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 5025

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antidepressants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 45 USPATFULL on STN

AN 2003:99270 USPATFULL

TI Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same

IN Kamei, Shigeru, Takarazuka-shi, JAPAN

Ojima, Mami, Amagasaki-shi, JAPAN

Kitayoshi, Takahito, Suita-shi, JAPAN

Igari, Yasutaka, Kobe-shi, JAPAN

PI US 2003068374 A1 20030410

AI US 2002-204185 A1 20020819 (10)

WO 2001-JP1191 20010220

PRAI JP 2000-48980 20000221

DT Utility

FS APPLICATION

LREP WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021

CLMN Number of Claims: 39

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2121

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sustained-release preparation containing a physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer which are improved in the release-control and stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 45 USPATFULL on STN

AN 2003:99169 USPATFULL

TI Individualization of therapy with immunosuppressants

IN Leyland-Jones, Brian, Miami, FL, UNITED STATES

PA McGill University, Montreal, CANADA (2)

PI US 2003068273 A1 20030410

AI US 2002-100556 A1 20020314 (10)

PRAI US 2001-275489P 20010314 (60)

DT Utility

FS APPLICATION

LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

CLMN Number of Claims: 113

ECL Exemplary Claim: 1

DRWN 20 Drawing Page(s)

LN.CNT 5019

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with immunosuppressants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 45 USPATFULL on STN
AN 2003:78030 USPATFULL
TI Individualization of therapy with hyperlipidemia agents
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003053950 A1 20030320
AI US 2002-125690 A1 20020417 (10)
PRAI US 2001-284210P 20010418 (60)
DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 113
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5288

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with hyperlipidemia agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 45 USPATFULL on STN
AN 2003:71960 USPATFULL
TI Chemically-modified peptides, compositions, and methods of production
and use
IN Kuhner, Carla H., Avondale, PA, UNITED STATES
Romesser, James A., Kennett Square, PA, UNITED STATES
PI US 2003050247 A1 20030313
AI US 2001-882781 A1 20010615 (9)
PRAI US 2000-212441P 20000616 (60)
DT Utility
FS APPLICATION
LREP Patrick J. Farley, Ph.D., WOODCOCK WASHBURN KURTZ, MACKIEWICZ & NORRIS
LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 3324

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for inhibiting and controlling the growth of
microbes are disclosed. The composition comprises at least one
chemically-modified peptide with antimicrobial activity and at least one
carrier. The method comprises of administering an amount, effective for
the prevention, inhibition and termination of microbial growth for
industrial, pharmaceutical, household and personal care use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 45 USPATFULL on STN
AN 2003:70919 USPATFULL
TI Individualization of therapy with gastroesophageal reflux disease agents
IN Leyland-Jones, Brian, Miami, FL, UNITED STATES
PA McGill University, Montreal, CANADA (U.S. corporation)
PI US 2003049204 A1 20030313
AI US 2002-132080 A1 20020424 (10)
PRAI US 2001-285687P 20010424 (60)

DT Utility
FS APPLICATION
LREP HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX
9133, CONCORD, MA, 01742-9133
CLMN Number of Claims: 83
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 5184
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the individualization of therapy on the basis
of a phenotypic profile of an individual. More specifically, the present
invention relates to the use of metabolic phenotyping for the
individualization of treatment with GERD agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 45 USPATFULL on STN
AN 2002:239149 USPATFULL
TI Anilinopeptide derivatives
IN Fassler, Alexander, Arlesheim, SWITZERLAND
Bold, Guido, Gipf-Oberfrick, SWITZERLAND
Capraro, Hans-Georg, Rheinfelden, SWITZERLAND
Lang, Marc, Mulhouse, FRANCE
PA Novatis AG, Basel, SWITZERLAND (non-U.S. corporation)
PI US 6451973 B1 20020917
WO 9803476 19980129
AI US 1999-214959 19990201 (9)
WO 1997-EP3804 19970716
19990201 PCT 371 date
PRAI CH 1996-1788 19960717
DT Utility
FS GRANTED
EXNAM Primary Examiner: Low, Christopher S. F.; Assistant Examiner: Lukton,
David
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to compounds of the formula I, ##STR1##

in which

R.sub.1 and R.sub.2 are, independently of each other, lower alkyl or
lower alkoxy-lower alkyl;

R.sub.3 and R.sub.4 are, independently of each other, sec-lower alkyl or
tert-lower alkyl;

R.sub.5 is phenyl or cyclohexyl; and

R.sub.6 and R.sub.7 are, independently of each other, lower alkyl, or,
together with the linking nitrogen atom, pyrrolidino, piperidino,
4-lower alkylpiperidino, 1,2,4-triazol-1-yl or 1,2,4-triazol-4-yl;

or a salt thereof, provided that at least one salt-forming group is
present.

These compounds are inhibitors of HIV protease and are therefore
suitable, for example, for treating AIDS or its preliminary stages.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 45 USPATFULL on STN
AN 2002:213474 USPATFULL
TI Wound healing compound
IN Peshoff, Mickey L., Sulphur, LA, UNITED STATES
PI US 2002114847 A1 20020822
US 6660306 B2 20031209
AI US 2002-125165 A1 20020418 (10)
RLI Continuation-in-part of Ser. No. US 2000-689087, filed on 12 Oct 2000,
PENDING
DT Utility
FS APPLICATION
LREP THOMAS S. KEATY, KEATY PROFESSIONAL LAW CORP., 2140 WORLD TRADE CENTER,
NO. 2 CANAL STREET, NEW ORLEANS, LA, 70130
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2238

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprise a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) **zinc oxide** and (b) fat-soluble vitamins. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the antibacterial/antifungal-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 45 USPATFULL on STN
AN 2002:186101 USPATFULL
TI Anti-viral composition
IN Killam, Harold, Melrose, MA, UNITED STATES
PI US 2002099022 A1 20020725
US 6500808 B2 20021231
AI US 2001-39968 A1 20011019 (10)
RLI Division of Ser. No. US 2000-608029, filed on 30 Jun 2000, PENDING
DT Utility
FS APPLICATION
LREP PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE,
BOSTON, MA, 02199
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 1123

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to **zinc-containing antiviral** compositions and methods of treating viral infections. More specifically, the invention provides compositions and methods useful for ameliorating the symptoms of individuals suffering from infection with a broad range of viruses. Examples of viruses against which the compounds of the invention are active include rhinoviruses, varicella zoster, immunodeficiency viruses, including HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 45 USPATFULL on STN
AN 2002:98924 USPATFULL

TI Peptides, compositions and methods for the treatment of burkholderia
cepacia
IN Kuhner, Carla H., Avondale, PA, UNITED STATES
Romesser, James A., Kennett Square, PA, UNITED STATES
PI US 2002051819 A1 20020502
AI US 2001-881954 A1 20010615 (9)
PRAI US 2000-212440P 20000616 (60)
DT Utility
FS APPLICATION
LREP WOODCOCK WASHBURN KURTZ, MACKIEWICZ & NORRIS LLP, 46th Floor, One
Liberty Place, Philadelphia, PA, 19103
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 2739

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Peptides, compositions and methods for inhibiting and controlling the
growth of Burkholderia cepacia are disclosed. The composition comprises
a peptide mixture with antimicrobial activity against Burkholderia
cepacia and at least one carrier. The method comprises delivering an
amount, effective for the prevention, inhibition and termination of the
growth of Burkholderia cepacia for industrial, pharmaceutical,
household, and personal care use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 45 USPATFULL on STN
AN 2002:92041 USPATFULL
TI Topical delivery systems for active agents
IN Niemiec, Susan M., Yardley, PA, UNITED STATES
Wang, Jonas C.T., Robbinsville, NJ, UNITED STATES
Wisniewski, Stephen J., Doylestown, PA, UNITED STATES
Stenn, Kurt S., Princeton, NJ, UNITED STATES
Lu, Gwang Wei, Plainsboro, NJ, UNITED STATES
PI US 2002048558 A1 20020425
US 6419913 B2 20020716
AI US 2001-916019 A1 20010726 (9)
RLI Continuation of Ser. No. US 1999-360412, filed on 23 Jul 1999, GRANTED,
Pat. No. US 6284234
PRAI US 1998-95289P 19980804 (60)
DT Utility
FS APPLICATION
LREP AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON
PLAZA, NEW BRUNSWICK, NJ, 08933-7003
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 1881

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method for enhancing the transmembrane
penetration of benefit agents using a certain non-ionic
lipid/surfactant-containing formulation as an enhancing agent, and the
compositions used therein. Various active agents, such as anti-dandruff
agents, hair growth agents, hair inhibitor agents, anti-acne agents,
anti-aging agents, depilatory agents, and depigmentation agents, may be
effectively delivered into the skin, hair follicles and sebaceous glands
using the compositions of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 45 USPATFULL on STN
AN 2001:173761 USPATFULL

TI Antivirally active heterocyclic azahehexane derivatives
 IN Fassler, Alexander, Macclesfield, United Kingdom
 Bold, Guido, Gipf-Oberfrick, Switzerland
 Capraro, Hans-Georg, Rheinfelden, Switzerland
 Lang, Marc, Mulhouse, France
 Khanna, Satish Chandra, Bottmingen, Switzerland
 PA Novartis Finance Corporation, New York, NY, United States (U.S.
 corporation)
 PI US 6300519 B1 20011009
 AI US 1999-448328 19991123 (9)
 RLI Division of Ser. No. US 1998-108481, filed on 1 Jul 1998, now patented,
 Pat. No. US 6110946
 PRAI CH 1996-1018 19960422
 CH 1997-223 19970131
 DT Utility
 FS GRANTED
 EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
 LREP Pfeiffer, Hesna J.
 CLMN Number of Claims: 1
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4875
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB There are described compounds of formula I*, ##STR1##

 wherein

 R.sub.1 is lower alkoxy carbonyl,

 R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower
 alkyl,

 R.sub.3 is phenyl that is unsubstituted or substituted by one or more
 lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,

 R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by
 unsaturated heterocyclyl that is bonded by way of a ring carbon atom,
 has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected
 from nitrogen, oxygen, sulfur, suffinyl (--SO--) and sulfonyl
 (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by
 phenyl-lower alkyl,

 R.sub.5, independently of R.sub.2, has one of the meanings mentioned for
 R.sub.2, and

 R.sub.6, independently of R.sub.1, is lower alkoxy carbonyl,

 or salts thereof, provided that at least one salt-forming group is
 present.

 The compounds are inhibitors of retroviral aspartate protease and can be
 used, for example, in the treatment of AIDS. They exhibit outstanding
 pharmacodynamic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 45 USPATFULL on STN
 AN 2001:147452 USPATFULL
 TI Topical delivery systems for active agents
 IN Niemiec, Susan M., Yardley, PA, United States
 Wang, Jonas C. T., Robbinsville, NJ, United States
 Wisniewski, Stephen J., Doylestown, PA, United States

Stenn, Kurt S., Princeton, NJ, United States
Lu, Gwang Wei, Plainsboro, NJ, United States
PA Johnson & Johnson Consumer Companies, Inc., Skillman, NJ, United States
(U.S. corporation)
PI US 6284234 B1 20010904
AI US 1999-360412 19990723 (9)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Criares, Theodore J.; Assistant Examiner: Kim,
Jennifer
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1844

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method for enhancing the transmembrane penetration of benefit agents using a certain non-ionic lipid/surfactant-containing formulation as an enhancing agent, and the compositions used therein. Various active agents, such as anti-dandruff agents, hair growth agents, hair inhibitor agents, anti-acne agents, anti-aging agents, depilatory agents, and depigmentation agents, may be effectively delivered into the skin, hair follicles and sebaceous glands using the compositions of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 45 USPATFULL on STN
AN 2000:174631 USPATFULL
TI Combinations of HIV protease inhibitors with reverse transcriptase inhibitors
IN Fassler, Alexander, Macclesfield, United Kingdom
Bold, Guido, Gipf-Oberfrick, Switzerland
Capraro, Hans-Georg, Rheinfelden, Switzerland
Lang, Marc, Mulhouse, France
Khanna, Satish Chandra, Bottmingen, Switzerland
PA Novartis Finance Corporation, New York, NY, United States (U.S. corporation)
PI US 6166004 20001226
AI US 1999-399627 19990920 (9)
RLI Continuation of Ser. No. US 1998-108481, filed on 1 Jul 1998
PRAI CH 1996-1018 19960422
CH 1997-223 19970131
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Desai, Rita
LREP Pfeiffer, Hesna J.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4848

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxy carbonyl,

R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,

R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,

R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom,

has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,

R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, and

R.sub.6, independently of R.sub.1, is lower alkoxycarbonyl,

or salts thereof, provided that at least one salt-forming group is present.

The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. They exhibit outstanding pharmacodynamic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 45 USPATFULL on STN
AN 2000:113973 USPATFULL
TI Antivirally active heterocyclic azahexane derivatives
IN Fassler, Alexander, Macclesfield, United Kingdom
Bold, Guido, Gipf-Oberfrick, Switzerland
Capraro, Hans-Georg, Rheinfelden, Switzerland
Lang, Marc, Mulhouse, France
Khanna, Satish Chandra, Bottmingen, Switzerland
PA Novartis Finance Corporation, Summit, NJ, United States (U.S. corporation)
PI US 6110946 20000829
AI US 1998-108481 19980701 (9)
RLI Division of Ser. No. US 1997-831630, filed on 9 Apr 1997, now patented, Pat. No. US 5849911
PRAI CH 1996-1018 19960422
CH 1997-223 19970131
DT Utility
FS Granted
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita J.
LREP Pfeiffer, Hesna J.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4897

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxycarbonyl,

R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,

R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,

R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,

R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, and

R.sub.6, independently of R.sub.1, is lower alkoxy-carbonyl,
or salts thereof, provided that at least one salt-forming group is present.

The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. They exhibit outstanding pharmacodynamic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 45 USPATFULL on STN
AN 1998:157509 USPATFULL
TI Antivirally active heterocyclic azahexane derivatives
IN Fassler, Alexander, Macclesfield, Great Britain
Bold, Guido, Gipf-Oberfrick, Switzerland
Capraro, Hans-Georg, Rheinfelden, Switzerland
Lang, Marc, Mulhouse, France
Khanna, Satish Chandra, Bottmingen, Switzerland
PA Novartis Finance Corporation, Summit, NJ, United States (U.S. corporation)
PI US 5849911 19981215
AI US 1997-831630 19970409 (8)
PRAI CH 1996-1018 19960422
CH 1997-223 19970131
DT Utility
FS Granted
EXNAM Primary Examiner: Clardy, S. Mark; Assistant Examiner: Qazi, Sabiha N.
LREP Pfeiffer, Hesna J.
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4909

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described compounds of formula I*, ##STR1## wherein R.sub.1 is lower alkoxy-carbonyl,

R.sub.2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl,

R.sub.3 is phenyl that is unsubstituted or substituted by one or more lower alkoxy radicals, or C.sub.4 -C.sub.8 cycloalkyl,

R.sub.4 is phenyl or cyclohexyl each substituted in the 4-position by unsaturated heterocyclyl that is bonded by way of a ring carbon atom, has from 5 to 8 ring atoms, contains from 1 to 4 hetero atoms selected from nitrogen, oxygen, sulfur, sulfinyl (--SO--) and sulfonyl (--SO.sub.2 --) and is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl,

R.sub.5, independently of R.sub.2, has one of the meanings mentioned for R.sub.2, and

R.sub.6, independently of R.sub.1, is lower alkoxy-carbonyl,

or salts thereof, provided that at least one salt-forming group is present.

The compounds are inhibitors of retroviral aspartate protease and can be used, for example, in the treatment of AIDS. They exhibit outstanding pharmacodynamic properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 45 USPATFULL on STN
AN 97:66160 USPATFULL
TI Therapeutic-wound healing compositions and methods for preparing and using same
IN Martin, Alain, 31 Country Club Dr., Ringoes, NJ, United States 08551
PI US 5652274 19970729
AI US 1995-445813 19950522 (8)
RLI Continuation-in-part of Ser. No. US 1994-187435, filed on 27 Jan 1994, now abandoned which is a continuation of Ser. No. US 1991-798392, filed on 26 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Barish, Jean B.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 90 Drawing Figure(s); 77 Drawing Page(s)
LN.CNT 9592

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells. In one embodiment, the therapeutic wound healing composition comprises (a) pyruvate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In another embodiment, the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In yet another embodiment, the therapeutic wound healing composition comprises (a) an antioxidant and (b) a mixture of saturated and unsaturated fatty acids. In still yet another embodiment, the therapeutic wound healing composition comprises (a) lactate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. This invention also pertains to wound healing compositions combined with a medicament which is useful for treating injured mammalian cells to form augmented wound healing compositions such as immunostimulating-wound healing compositions, **antiviral** -wound healing compositions, antikeratolytic-wound healing compositions, anti-inflammatory-wound healing compositions, antifungal-wound healing compositions, acne treating-wound healing compositions, sunscreen-wound healing compositions, dermatological-wound healing compositions, antihistamine-wound healing compositions, antibacterial-wound healing compositions, and bioadhesive-wound healing compositions. This invention also pertains to wound healing compositions combined with a cytotoxic agent to form cytoprotective-wound healing compositions useful for protecting and reducing injury to mammalian cells and to razor cartridges comprising the wound healing compositions. This invention also pertains to methods for preparing and using the wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 45 OF 45 USPATFULL on STN
AN 97:12521 USPATFULL
TI Dermatological wound healing compositions and methods for preparing and using same
IN Martin, Alain, Ringoes, NJ, United States
Nayak, Ammunje S., Great Meadows, NJ, United States
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

PI US 5602183 19970211
AI US 1995-446964 19950522 (8)
RLI Continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993,
now abandoned which is a continuation of Ser. No. US 1991-663500, filed
on 1 Mar 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Barish, Jean B.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 3460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to therapeutic dermatological-wound healing compositions useful to minimize and treat diaper dermatitis. The compositions comprise a therapeutically effective amount of a buffering agent to maintain the pH of the dermatitis in a range from about 5 to about 8, an anti-inflammatory agent, and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; (c) a mixture of saturated and unsaturated fatty acids. The therapeutic dermatological-wound healing compositions may be utilized in a wide variety of topical pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic dermatological-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.